PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Strontium ranelate - Osteoporosis

PAD Profile : Strontium ranelate - Osteoporosis

Brand Names Include :
Aristo

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
02 June 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Strontium ranelate (Aristo) granules for oral suspension are a specilalist treament option (RED status) for severe osteoporosis in patients who are intolerant to or contraindicated for other therapies. See Osteoporosis Assessment and Treatment Guidelines below.

The Osteoporosis guidelines have been reviewed and updated.
The guidelines are supported by two algorithms which have been extracted from the guideline and provided as separate documents (below) for ease of use:
Algorithm 1 - Treatment Pathway for adults
Algorithm 2 - Review of Long-term Bisphosphonate Therapy 
 

Associated BNF Codes

06. Endocrine System
06.06.02. Bisphosphonates and other drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More